Small cell lung cancer (SCLC) is an aggressive tumor characterized by rapid doubling time
and high propensity for early development of disseminated disease. Although most patients …

Inhibition of angiogenesis has been demonstrated to be an efficacious strategy in treating
several tumors. Vascular endothelial growth factor (VEGF) is the most important protein with …

The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Small Cell Lung
Cancer (SCLC) provide recommended management for patients with SCLC, including …

Purpose Considering promising results in phase II studies, a randomized phase III trial was
designed to assess the efficacy of adding bevacizumab to first-line cisplatin plus etoposide …

Small cell lung cancer (SCLC) is an aggressive malignancy with a distinct natural history
and dismal prognosis. Given its predisposition for early dissemination, patients are …

Importance Combinations of chemotherapy with immunotherapy or bevacizumab in first-line
treatments of extensive-stage small cell lung cancer (ES-SCLC) have been evaluated in …

Background Bevacizumab is a humanised monoclonal antibody which blocks the binding of
circulating vascular endothelial growth factor to its receptors. To date, the Food and Drug …

PURPOSE To provide evidence-based recommendations to practicing clinicians on the
management of patients with small-cell lung cancer. METHODS An Expert Panel of medical …

Small-cell lung cancer (SCLC) is characterized by aggressive disease progression and
tendency to metastasize. Although chemotherapy for extensive-stage SCLC (ES-SCLC) has …

For many years the standard of care for small cell lung cancer (SCLC) has remained
unchanged. Despite decades of active research, current treatment options are limited and …